SELLAS Life Sciences Group, Inc. (SLS)

4.17 +0.40 (+10.61%) USD  |  NASDAQ  |  Jan 02, 12:03
More

SELLAS Life Sciences Group Revenue Estimates for Next Fiscal Year

Revenue Estimates for Next Fiscal Year Chart

View Revenue Estimates for Next Fiscal Year for SLS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue Estimates for Next Fiscal Year Chart
Start Trial

Historical Data

View Historical Data
Start Trial

Revenue Estimates for Next Fiscal Year Range, Past 5 Years

View Revenue Estimates for Next Fiscal Year Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue Estimates for Next Fiscal Year Benchmarks

View Revenue Estimates for Next Fiscal Year Benchmarks
Start Trial
GT Biopharma, Inc. Upgrade
Geron Corp. Upgrade
ADMA Biologics, Inc. Upgrade
Lyell Immunopharma, Inc. Upgrade
NovaBay Pharmaceuticals, Inc. Upgrade

Revenue Estimates for Next Fiscal Year Related Metrics

EPS Estimates for Current Quarter Upgrade
EPS Estimates for Next Quarter Upgrade
EPS Estimates for Current Fiscal Year Upgrade
EPS Estimates for Next Fiscal Year Upgrade